After 6.8 million doses, US FDA pauses use of Johnson & Johnson Covid-19 vaccine over 6 adverse cases

The US Food and Drug Administration has recommended a pause in the use of the Johnson & Johnson Covid-19 vaccine as a precautionary measure after 6 cases of a rare and severe type of blood clot in individuals was detected.

In a statement, US FDA said that even though the adverse effects seem very rare, it is reviewing the data along with the Centers for Disease Control and Prevention.

So far, 6.8 million Americans have so far been administered the Johnson & Johnson Covid-19 vaccine. 

However, urging the US States to halt the usage of the vaccine, for now, the FDA said that the CDC will convene a meeting of the Advisory Committee on Immunization Practices on Wednesday to review the adverse cases. 

Until that process is complete, we are recommending this pause. This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot, the FDA said.

Dismissing criticism from certain people that 6 likely cases in over 6.8 million jabs were hardly any reason to halt its administering, the US FDA said that Covid-19 vaccine safety is a top priority for the government and that all reports of health problems following the vaccination are taken very seriously.

For more reliable and latest news subscribe to Asianet Newsable WhatsApp channel by clicking here.

• Covid vaccine
• Covid-19 vaccine
• US FDA
• covid-19
• johnson & johnson
• Centers for Disease Control and Prevention
• US CDC
• Vaccine adverse reaction
• blood clot
• Vaccine review